The American Statistical Association and DIA have created an interdisciplinary working group of drug safety experts from academia, industry and regulatory backgrounds to explore the future direction for safety monitoring. This introduction to the series explains the background and rationale for this special section.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/2168479018793130 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synergistic effect of proanthocyanidins and cefquinoxime sulfate on methicillin-resistant Staphylococcus aureus.
Pak J Pharm Sci
January 2025
Innovation Center Laboratory for Traditional Chinese Veterinary Medicine (TCVM), College of Veterinary Medicine, China Agricultural University, Beijing, China.
To address the severe problem of methicillin-resistant Staphylococcus aureus (MRSA) resistance, this study identified a single component from traditional Chinese medicine that, when used in combination with existing antibiotics, enhances the therapeutic efficacy of the antimicrobial drugs. Using the micro broth dilution method and the checkerboard dilution method, susceptibility tests were conducted on ten commonly used β-lactam antibiotics against eleven strains of MRSA. It was found that cefquinome sulfate exhibits synergistic activity with PROs.
View Article and Find Full Text PDFCadmium translocation combined with metabolomics analysis revealed potential mechanisms of MT@MSN-CS and GSH@MSN-CS in reducing cadmium accumulation in rice (Oryza sativa L.) grains.
Environ Sci Pollut Res Int
January 2025
Key Laboratory of Water Pollution Control and Environmental Safety of Zhejiang Province, Department of Environmental Engineering, Zhejiang University, Zhejiang Province, Hangzhou, 310058, P.R. China.
Applying nano-delivery systems for phytohormones via foliar application has proven effective in reducing grain cadmium (Cd) levels in crops. However, the mechanisms underlying this reduction remain inadequately understood. This study integrated the determination of leaf photosynthetic parameters, Cd translocation analysis, and metabolomics to elucidate the effects of reduced glutathione (GSH) and melatonin (MT), delivered with or without chitosan-encapsulated mesoporous silica nanoparticles (MSN-CS), on grain Cd levels in rice.
View Article and Find Full Text PDFReal-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.
Clin Lymphoma Myeloma Leuk
December 2024
Icahn School of Medicine at Mount Sinai, New York, NY.
Background: This analysis explored real-world characteristics, treatment patterns and clinical outcomes in patients with relapsed or refractory multiple myeloma (RRMM) previously treated with lenalidomide and an anti-CD38 monoclonal antibody (mAb) and requiring subsequent treatment.
Materials And Methods: The PREAMBLE and Connect MM prospective registries of patients with multiple myeloma (MM), and the US nationwide Flatiron Health electronic health record-derived de-identified database were analysed. MM-specific treatment patterns (prior/index therapies) and outcomes (progression-free survival [PFS]/overall survival [OS]) were assessed.
Axial spondyloarthritis.
Lancet
January 2025
Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany.
Axial spondyloarthritis manifests as a chronic inflammatory disease primarily affecting the sacroiliac joints and spine. Although chronic back pain and spinal stiffness are typical initial symptoms, peripheral (ie, enthesitis, arthritis, and dactylitis) and extra-musculoskeletal (ie, uveitis, inflammatory bowel disease, and psoriasis) manifestations are also common. Timely and accurate diagnosis is challenging and relies on identifying a clinical pattern with a combination of clinical, laboratory (HLA-B27 positivity), and imaging findings (eg, structural damage on pelvic radiographs and bone marrow oedema on MRI of the sacroiliac joints).
View Article and Find Full Text PDFEfficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
January 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!